Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-005250
Filing Date
2018-01-24
Accepted
2018-01-24 19:06:51
Documents
1
Period of Report
2018-01-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3025
  Complete submission text file 0001209191-18-005250.txt   4716
Mailing Address 4085 CAMPBELL AVENUE, SUITE 200 MENLO PARK CA 94025
Business Address 4085 CAMPBELL AVENUE, SUITE 200 MENLO PARK CA 94025 650-486-1416
Menlo Therapeutics, Inc. (Issuer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 415-522-0100
venBio Global Strategic Fund II L.P. (Reporting) CIK: 0001634632 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38356 | Film No.: 18546358